Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

BACKGROUND: Therapeutic cancer vaccines have shown activity in metastatic castration-resistant prostate cancer (mCRPC), and methods are being assessed to enhance their efficacy. Ipilimumab is an antagonistic monoclonal antibody that binds cytotoxic T-lymphocyte-associated protein 4, an immunomodulat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Madan, Ravi A, Mohebtash, Mahsa, Arlen, Philip M, Vergati, Matteo, Rauckhorst, Myrna, Steinberg, Seth M, YTsang, Kwong, Poole, Diane J, Parnes, Howard L, Wright, John J, Dahut, William L, Schlom, Jeffrey, Gulley, James L
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6359905/
https://ncbi.nlm.nih.gov/pubmed/22326924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70006-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados